Integrated microfluidic immunoassays for point-of-care diagnostic measurement of human serum cystatin C in chronic kidney disease

Cystatin C (CYS-C) is considered superior to creatinine as a serum biomarker of estimated glomerular filtration rate (eGFR) for chronic kidney disease (CKD) assessment. It is minimally influenced by non-filtration-specific factors such as muscle mass, age and gender. However, currently CYS-C testing is limited to specialized diagnostic labs and no point-of-care (PoC) tools are clinically available. To address this gap, we leveraged the enabling power of microfluidic devices for PoC tests of CYS-C. Among the microfluidic devices, PDMS-based wet chips and paper-based dry chips have been widely used for disease biomarker measurements with their respective advantages and limitations. Therefore, in this study, we developed a PDMS-based microfluidic immunoturbidity chip allowing side-scattering optical measurement and a paper-based microfluidic lateral flow immunoassay chip plus a novel electric field-assisted antibody loading protocol for quantitative CYS-C tests. We demonstrated that both chips meet the clinical requirements of the serum CYS-C detection range and limit. Importantly, each type of microfluidic chip is integrated with a custom-developed portable reader as PoC test prototypes. In validation studies using serum samples from CKD patients, both chip tests showed a similar agreement level with the traditional well plate-based immunoturbidity assay test results. As an integrated PoC test system, the microfluidic CYS-C paper chip test showed higher accuracy in determining the eGFR range based on several clinically relevant grouping criteria compared to the turbidity chip test. Collectively, these integrated microfluidic assays offer practical solutions for decentralized PoC diagnostic tests of CKD with competitive advantages over existing methods. • Developed two types of microfluidic devices for point-of-care testing of serum cystatin C. • Developed two portable readers, one for each type of microfluidic device. • The developed microfluidic systems were effectively applied to test clinical samples.

Authors

Institutions

Publication Details

Journal
Sensors and Actuators B Chemical
Published
2025-10-09
DOI
https://doi.org/10.1016/j.snb.2025.138880
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrated microfluidic immunoassays for point-of-care diagnostic measurement of human serum cystatin C in chronic kidney disease

AbdulRazaq Sokoro, René P. Zahedi, Xiaoou Ren, Dumitru Tomsa et al.
Sensors and Actuators B Chemical
Dialysis and Renal Disease Management
article

Integrated microfluidic immunoassays for point-of-care diagnostic measurement of human serum cystatin C in chronic kidney disease

AbdulRazaq Sokoro, René P. Zahedi, Xiaoou Ren, Dumitru Tomsa, Francis Lin, Amanda Stefanson, Paul Komenda, Ali Akbar Abolfathi, Yang Liu, Navdeep Tangri, Claudio Rigatto, Nicholas Palmerley
article en

Abstract

Cystatin C (CYS-C) is considered superior to creatinine as a serum biomarker of estimated glomerular filtration rate (eGFR) for chronic kidney disease (CKD) assessment. It is minimally influenced by non-filtration-specific factors such as muscle mass, age and gender. However, currently CYS-C testing is limited to specialized diagnostic labs and no point-of-care (PoC) tools are clinically available. To address this gap, we leveraged the enabling power of microfluidic devices for PoC tests of CYS-C. Among the microfluidic devices, PDMS-based wet chips and paper-based dry chips have been widely used for disease biomarker measurements with their respective advantages and limitations. Therefore, in this study, we developed a PDMS-based microfluidic immunoturbidity chip allowing side-scattering optical measurement and a paper-based microfluidic lateral flow immunoassay chip plus a novel electric field-assisted antibody loading protocol for quantitative CYS-C tests. We demonstrated that both chips meet the clinical requirements of the serum CYS-C detection range and limit. Importantly, each type of microfluidic chip is integrated with a custom-developed portable reader as PoC test prototypes. In validation studies using serum samples from CKD patients, both chip tests showed a similar agreement level with the traditional well plate-based immunoturbidity assay test results. As an integrated PoC test system, the microfluidic CYS-C paper chip test showed higher accuracy in determining the eGFR range based on several clinically relevant grouping criteria compared to the turbidity chip test. Collectively, these integrated microfluidic assays offer practical solutions for decentralized PoC diagnostic tests of CKD with competitive advantages over existing methods. • Developed two types of microfluidic devices for point-of-care testing of serum cystatin C. • Developed two portable readers, one for each type of microfluidic device. • The developed microfluidic systems were effectively applied to test clinical samples.

Sensors and Actuators B ChemicalVol. 448
Anhui University (CN), Research Manitoba (CA), University of Manitoba (CA)
Openalex Percentile: Top 70%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.